--- title: 'Clinical Daily Summary: What Happened on October 28, 2026' headline: Lilly’s retatrutide beats Ozempic on weight loss in diabetes study description: Vanda reported fewer vomiting episodes with tradipitant. Idorsia has started a redesigned Phase 3 study of its Fabry disease drug. url: https://thebench.bio/news/clinical/2026-10-28 topic: clinical date: '2026-10-28' covers: - '2026-10-28' date_published: '2026-10-28T12:02:35Z' date_modified: '2026-10-28T12:02:35Z' tags: - Clinical - Research sources: 6 publisher: TheBench.Bio --- # Clinical Daily Summary: What Happened on October 28, 2026 **Lilly’s retatrutide beats Ozempic on weight loss in diabetes study** Vanda reported fewer vomiting episodes with tradipitant. Idorsia has started a redesigned Phase 3 study of its Fabry disease drug. ## Today in brief Eli Lilly said retatrutide lowered A1c and body weight more than Ozempic in a head-to-head diabetes study. [1] [2] At the highest dose, weight loss was 20.9% with retatrutide and 9.4% with Ozempic among participants who stayed on treatment. [1] In Vanda’s Phase 3 trial, fewer participants vomited after taking tradipitant with semaglutide than after taking placebo. [3] Idorsia has opened a Phase 3 trial of lucerastat for Fabry disease, focusing its development plan on kidney deposits. [4] ## Retatrutide outperformed Ozempic on weight and A1c Eli Lilly said retatrutide performed better than Ozempic on blood sugar and weight measures in a head-to-head diabetes study. [1] After 80 weeks, A1c fell by 2.2 percentage points with the highest retatrutide dose and by 1.8 points with Ozempic. [1] Participants taking the highest retatrutide dose lost 20.9% of their weight, compared with 9.4% for those taking Ozempic. [1] Those weight-loss figures include participants who remained on treatment, not the full study population. [1] ## Vanda reports fewer GLP-1-related vomiting episodes with tradipitant Vanda said its Phase 3 Study 3601 found less vomiting with oral tradipitant than with placebo in people given semaglutide, a GLP-1 receptor agonist. [3] Participants received one 1 mg dose of semaglutide, without the usual gradual dose increases, in a trial setup expected to provoke vomiting. [3] Vomiting occurred in 43.0% of tradipitant recipients and 58.5% of placebo recipients, a site-adjusted relative reduction of 27%. [3] Vomiting with severe nausea occurred in 33.1% and 50.6%, respectively, a 35% adjusted relative decrease. [3] Frequent vomiting, defined as more than two episodes on multiple days, affected 6.3% of the tradipitant group and 15.9% of the placebo group. [3] Vanda plans to discuss the combined Phase 2 and Phase 3 findings with regulators and submit a supplemental new drug application to the FDA for this use. [3] ## Idorsia starts a new Phase 3 trial of lucerastat in Fabry disease Idorsia began FAB-KLEAR, a pivotal Phase 3 study of lucerastat in adult men with Fabry disease, shifting its development focus to kidney deposits. [4] The company’s earlier MODIFY trial missed its primary endpoint, neuropathic pain, although lower levels of the disease-related substance Gb3 indicated biological activity. [4] FAB-KLEAR plans to enroll 16 men and assess kidney biopsy scores after 18 months, with no placebo group. [4] Idorsia also plans FAB-SWITCH, a 74-person study that will compare lucerastat with enzyme replacement therapy and assess kidney function. [4] Nxera exercised an option to pay 7 million Swiss francs and support global Phase 3 development for exclusive rights in Japan, South Korea, Taiwan, and certain other Asia-Pacific markets, excluding China. [4] Idorsia is targeting a possible regulatory filing as early as 2029. [4] ## Also worth knowing - The MOIO trial did not establish non-inferior progression-free survival with checkpoint inhibitors given every 12 weeks and showed a possible signal of worse survival. [5] - Walmart Healthcare Research Institute and Care Access plan to open three clinical trial centers in Las Vegas, Livonia, and San Antonio in the first half of 2027. [6] ## The day in numbers - **20.9% vs. 9.4%**: Weight loss with the highest retatrutide dose versus Ozempic among participants who stayed on treatment. [1] - **43.0% vs. 58.5%**: Participants reporting vomiting with tradipitant versus placebo after semaglutide dosing. [3] - **7 million Swiss francs**: Nxera’s payment for specified Asia-Pacific rights to lucerastat and support for its Phase 3 development. [4] ## Also published - [What It Would Take to Make Community Trials Accessible and Scalable](), Applied Clinical Trials - [AbbVie bids to join the BCMA crowd with etentamig](), pharmaphorum - [ACT Brief: Legacy Trial Workflows, Medical Writing Talent Gaps, and Post-Exposure COVID Prevention](), Applied Clinical Trials - [Should There be More of a Focus on Developing Preventative Medications](), Pharmaceutical Executive - [Why Legacy Trial Workflows Weigh So Heavily on Community and Rural Clinics](), Applied Clinical Trials ## Sources 1. [STAT+: Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study](), STAT Biotech, 2026-10-28 2. [Lilly's triple G overpowers Ozempic in diabetes trial](), pharmaphorum, 2026-10-28 3. [Vanda reports Phase III tradipitant trial data in GLP-1-associated vomiting](), Clinical Trials Arena, 2026-10-28 4. [Idorsia launches redesigned Fabry disease trial with Nxera backing](), European Biotechnology, 2026-10-28 5. [ESMO26: Standard dosing prevails over 12-week checkpoint inhibitors in MOIO trial](), Pharmaceutical Technology, 2026-10-28 6. [Walmart and Care Access to open three clinical trial centres in US](), Clinical Trials Arena, 2026-10-28 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: [4]: [5]: [6]: